Cetirizine is a histamine-1 receptor antagonist sold in the U.S. under 13 brand and generic names, for perennial allergic rhinitis, urticaria and pruritus. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Quzyttir (application NDA211415). Other cetirizine products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
QUZYTTIR is a single use injectable product for intravenous administration only. The recommended dosage regimen is once every 24 hours as needed for treatment of acute urticaria. Administer QUZYTTIR as an intravenous push over a period of 1 to 2 minutes. QUZYTTIR is not recommended in pediatric patients less than 6 years of age with impaired renal or hepatic function [see Pediatric Use ( 8.4 )]. If using as an antihistamine prior to infusion product administration, refer to infusion product prescribing information for instructions. For intravenous administration only ( 2 ) Recommended dosages: Adults and adolescents ≥ 12 years of age and older: 10 mg ( 2.1 ) Children 6 to 11 years: 5 mg or 10 mg ( 2.2 ) Children 6 months to 5 years: 2.5 mg ( 2.3 ) Recommended dosage regimen is once every 24 hours as needed for acute urticaria ( 2 ) 2.1 Adults and adolescents 12 years of age and older The recommended dosage is 10 mg administered by intravenous injection. 2.2 Children 6 to 11 years of age The recommended dosage is 5 mg or 10 mg depending on symptom severity administered by intravenous injection. 2.3 Children 6 months to 5 years of age The recommended dosage is 2.5 mg administered by intravenous injection.
The following clinically significant adverse reaction is described elsewhere in the labeling: Somnolence/Sedation [see Warnings and Precautions ( 5.1 )] The most common adverse reactions (incidence less than 1%) with QUZYTTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis. Most common adverse reactions (incidence equal to or greater than 2%) with use of oral cetirizine hydrochloride are somnolence, fatigue, dry mouth, pharyngitis, and dizziness. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, call TerSera Therapeutics LLC at 1-844-334-4035 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Oral cetirizine hydrochloride The following adverse reactions associated with the use of oral cetirizine hydrochloride were identified in clinical trials. In clinical trials in patients 12 years and older the most common adverse reactions to oral cetirizine hydrochloride occurring with a 2% or greater incidence and greater than placebo were somnolence (14%), fatigue (6%), dry mouth (5%), pharyngitis (2%), and dizziness (2%). In clinical trials in children 6 to…
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 70/100 | Over-the-counter | Solution | Generic | $0 | View → | |
| 2 | 70/100 | Over-the-counter | Solution |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| ZYRTEC;D | 5 mg / 120 mg | white | round | — |
| Zyrtec;D | 5 mg / 120 mg | white | round | — |
| 915 | 5 mg / 120 mg | white | round | — |
| L | 5 mg | white | oval | — |
| SG;136 | 5 mg | white | oval | — |
| H;LL | 5 mg |
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Cetirizine Hydrochloride Tablets USP 10 mg
Tablet/Capsules Imprinted with Wrong ID
JB Chemicals and Pharmaceuticals Ltd · Sep 12, 2025
Cetirizine Hydrochloride Tablets USP 10 mg
Tablet/Capsules Imprinted with Wrong ID
JB Chemicals and Pharmaceuticals Ltd · Sep 12, 2025
Cetirizine Hydrochloride Tablets
CGMP Deviations
Glenmark Pharmaceuticals Inc., USA · Mar 13, 2025
The elimination half-life of cetirizine is about 8.3 hours (mean in healthy adults). This is the parent drug's elimination half-life; cetirizine's only metabolite has negligible antihistaminic activity, so it does not prolong the effect. The half-life is shorter in young children (per the label, roughly 33-41% shorter in ages 2-5 and about 63% shorter in ages 6-23 months) and is expected to be longer in older adults and in people with kidney or liver impairment.
CETIRIZINE HYDROCHLORIDE syrup (DailyMed) ↗Half-life is how long the body takes to clear half a dose. It is not the same as how long a drug test can detect it, and it varies with age, kidney and liver function.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
The use of QUZYTTIR is contraindicated in patients with a known hypersensitivity to cetirizine hydrochloride or any of its ingredients, levocetirizine, or hydroxyzine. Known hypersensitivity to cetirizine hydrochloride or any of its ingredients, levocetirizine, or hydroxyzine ( 4 )
No clinically significant drug interactions with oral cetirizine hydrochloride, the active ingredient in QUZYTTIR, have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin. There was a small decrease in the clearance of oral cetirizine hydrochloride caused by a 400-mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect [see Clinical Pharmacology ( 12.3 )].
| Generic |
| $0 |
| View → |
| 3 | 64/100 | Over-the-counter | Solution | Generic | $0 | View → |
| 4 | Not yet rated | Over-the-counter | Tablet | Generic | $0 | View → |
| 5 | Not yet rated | Over-the-counter | Tablet | Generic | $0 | View → |
| 6 | Not yet rated | Over-the-counter | Solution | Generic | $0 | View → |
| 7 | Not yet rated | Over-the-counter | Solution | Generic | $0 | View → |
| 8 | Not yet rated | Prescription | Tablet | Generic | $0 | View → |
| 9 | Not yet rated | Prescription | Injectable | Generic | $0 | View → |
| 10 | Not yet rated | Prescription | Solution | Generic | $0 | View → |
| white |
| oval |
| — |
| SG;136 | 5 mg | white | oval | — |
|---|
| G;4 | 10 mg | white | rectangle | — |
|---|
| CE;10 | 10 mg | white | round | — |
|---|
| CE;10 | 10 mg | white | round | — |
|---|
| L147 | 5 mg / 120 mg | white | round | — |
|---|
| L147 | 5 mg / 120 mg | white | round | — |
|---|